LY3127804

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for LY3127804, covering 2021-08-12 to 2025-10-23. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors [Phase 1]